Bicycle Therapeutics Analysis
What is Bicycle Therapeutics?
Precision-guided peptide therapeutics for solid tumors and beyond
Location
Cambridge, United Kingdom
Employees
201-500
Founded
2009
Product Features & Capabilities
- Bicycle® Toxin Conjugates (BTC®) targeting Nectin-4
- Bicycle® Tumor-Targeted Immune Cell Agonists (Bicycle TICA®) targeting Nectin-4 and CD137
- Bicycle® Radio Conjugates (BRC™) for radiopharmaceuticals
- Peptide therapeutics using phage display technology
Use Cases
Target Nectin-4 expressing tumors with BTC conjugates; Treat EphA2-positive cancers with BTC conjugates; Activate CD137 in tumor microenvironment via Bicycle TICA®; Deliver radiopharmaceuticals using BRC™ technology; Develop therapies for anti-infective, cardiovascular, and CNS diseases through partnerships
Other Considerations
Clinical-stage programs in active trials; Focus on undruggable targets like EphA2; Partnerships with academic and pharma leaders; Technology based on Nobel Prize-winning science; Headquartered in Cambridge, UK with US operations in Cambridge, MA
See something that needs updating? Suggest edits to this profile.
